Phase 3 Recruiting NIH
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Locations: - Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- Highlands Oncology Group - Rogers — Rogers, Arkansas
+ 321 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Locations: - NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente Dublin — Dublin, California
+ 276 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
+ 259 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Locations: - Local Institution - 007-556-A — Goodyear, Arizona
- USOR - Arizona Oncology - Prescott Valley — Prescott Valley, Arizona
- Local Institution - 007-568-A — Safford, Arizona
+ 217 more sites in the U.S.
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Locations: - Pioneer Research Center — Bullhead City, Arizona
- Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
+ 203 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Locations: - Research Site — Tucson, Arizona
- Research Site — Springdale, Arkansas
- Research Site — Anaheim, California
+ 74 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Locations: - Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center — Fullerton, California
- St. Jude Heritage Medical Group - Fullerton Plaza Multi-Specialty Clinic (Pulmonary Function Test) — Fullerton, California
+ 72 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Locations: - Alaska Oncology and Hematology ( Site 0039) — Anchorage, Alaska
- The University of Arizona Cancer Center - North Campus ( Site 0071) — Tucson, Arizona
- YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020) — Yuma, Arizona
+ 65 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- UC San Diego Health System - Encinitas — Encinitas, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Locations: - Local Institution - 0487 — Mobile, Alabama
- Southern Arizona VA Health Care System — Tucson, Arizona
- Local Institution - 0112 — Los Angeles, California
+ 49 more sites in the U.S.
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Locations: - Cancer and Blood Specialists of Arizona — Casa Grande, Arizona
- City of Hope Cancer Center Phoenix — Goodyear, Arizona
- Genesis Cancer Center — Hot Springs, Arkansas
+ 47 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Locations: - Local Institution - 0119 — Anchorage, Alaska
- Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
+ 41 more sites in the U.S.